Nan Fung Life Sciences
Mr. Batchelder’s most recent operational role was as co‑founder and CEO of Civitas Therapeutics (acquired by Acorda Therapeutics). Prior to Civitas he served as CEO of BIND Therapeutics (acquired by Pfizer) and Acceleron Pharma (acquired by Merck). He started his biotechnology career at Millennium Pharmaceutical serving in roles of increasing responsibility including SVP of Operations and where he played a leadership role in the launch of VELCADE® and was responsible for the commercial supply chain and technical operations for INTEGRLIN®. During his more than 30 years of executive leadership experience he also served in functional roles including operations, sales, marketing, business development, manufacturing, supply chain management and R&D. Mr. Batchelder currently serves as Executive Chair of XyloCor Therapeutics, Synchronicity Pharma and Kantum Pharma. He also serves on the board of the Michael J. Fox Foundation and was formerly chairman of MassBio. He received a BS in Chemical Engineering from Lehigh University.
This person is not in the org chart
This person is not in any offices
Nan Fung Life Sciences
Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Leveraging on Nan Fung Group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations, and investors in the life science space. Through direct investments via Pivotal bioVenture Partners funds (both in US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices, and diagnostics) and across different development stages, Nan Fung Life Sciences has a significant presence in both US and Greater China.